New small molecules for the treatment of Parkinson's disease

Expert Opinion on Investigational Drugs
Thomas Müller

Abstract

Parkinson's disease (PD) is characterized by a slowly ongoing neuronal death, which affects neurotransmitter metabolism and causes a wide variety of motor and non-motor features. Until now, therapy approaches have predominantly focused on motor behavior associated with dopamine substitution. This review aims to discuss putative reasons for recent failures of investigated treatment approaches, and to introduce currently tested and future compounds. We will describe how development programs of novel molecules now additionally consider non-motor features of PD as promising targets in order to obtain regulatory approval. Regulatory authorities increasingly exert influence on trial designs, demanding therapeutic effects that are not always clinically feasible given the variety of manifestations of the disease entity known as PD. In the past, research pitfalls have resulted in the failure of promising new compounds. Among the many reasons for this are massive placebo responses; the participation of too many investigators, with consequent wide variations of efficacy assessments; and a misconception of preclinical drug development, with models of PD that do not mimic its clinical nature. A few compounds are now being tested that have m...Continue Reading

References

Jan 1, 1979·Clinical Neurology and Neurosurgery·W BirkmayerB H Youdim
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Mar 4, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H PrzuntekH P Vogel
Nov 11, 1999·Archives of Neurology·L V MetmanT N Chase
Oct 18, 2000·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Mar 29, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzUNKNOWN Parkinson Study Group
Apr 3, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN Parkinson Study Group
Jun 1, 2002·Parkinsonism & Related Disorders·J Jankovic, C Hunter
Oct 11, 2002·Archives of Neurology·Clifford W ShultsUNKNOWN Parkinson Study Group
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Thomas Müller
Dec 21, 2002·Archives of Neurology·UNKNOWN Parkinson Study Group
Jul 3, 2003·Annals of Neurology·Alan L WhoneUNKNOWN REAL-PET Study Group
Aug 2, 2003·Annals of Neurology·Elaine K PerryRobert H Perry
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Anthony H V Schapira, C Warren Olanow
Feb 10, 2004·Journal of Neural Transmission·H PrzuntekP Riederer
Apr 21, 2004·Archives of Neurology·UNKNOWN Parkinson Study Group
May 11, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Carl E Clarke
May 19, 2004·Archives of Neurology·Thomas MüllerWilfried Kuhn
Aug 25, 2004·Neurology·F StocchiUNKNOWN Safinamide Parkinson's Study Group
Dec 14, 2004·The New England Journal of Medicine·Stanley FahnUNKNOWN Parkinson Study Group
Dec 21, 2004·Journal of Neurology, Neurosurgery, and Psychiatry·S ThomasI Gottlob
Oct 8, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Wolfgang H OertelJohannes Schwarz
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Thomas Müller, Hermann Russ
Nov 10, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Jan 3, 2007·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ruggero G Fariello
May 16, 2007·Archives of Neurology·Alexander StorchUNKNOWN German Coenzyme Q(10) Study Group
Jun 26, 2007·Disease-a-month : DM·Michael Rezak
Aug 4, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriAnthony H V Schapira
Nov 29, 2007·Pharmacotherapy·Hubert H Fernandez, Jack J Chen
Jan 5, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher G GoetzHermann Russ
Apr 9, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Natividad P Stover, Ray L Watts
May 29, 2008·Expert Review of Neurotherapeutics·Thomas Müller
Jun 11, 2008·Archives of Neurology·William J Weiner
Dec 2, 2008·Expert Opinion on Pharmacotherapy·Atheir Abbas, Bryan L Roth
Dec 17, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN TEMPO Open-label Study Group
Feb 7, 2009·Parkinsonism & Related Disorders·Laurent GrégoireThérèse Di Paolo

❮ Previous
Next ❯

Citations

Jun 12, 2012·Oxidative Medicine and Cellular Longevity·Sonia Gandhi, Andrey Y Abramov
Jun 6, 2012·Oxidative Medicine and Cellular Longevity·Philip Y Lam, Kam Ming Ko
Jul 26, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Carla I NietoJosé Luis Lavandera

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.